Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice
Thermo Fisher’s $13.6 billion bid for Life Technologies is a blockbuster move within the instrumentation and consumables space, and also has implications for clinical practice. It’s another sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth, along with the desire to move genomics tools into clinical use and the development of test content by nontraditional players in diagnostics.
You may also be interested in...
The resignation of CEO Alex Lukianov could signal a shift in the spine firm's approach to sales and profitability that could ultimately make NuVasive as a more attractive acquisition candidate.
Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.
GE Healthcare purchased Thermo Fisher’s research tools for $1 billion. Becton Dickinson acquires point-of-care diagnostic maker Alverix for $40 million. More news briefs.